Cardio Diagnostics
CDIO
30 hedge funds and large institutions have $52M invested in Cardio Diagnostics in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
80.91% more ownership
Funds ownership: 0% → 80.91% (+81%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Saba Capital Management
New York
|
+$4.64M |
| 2 |
Karpus Investment Management
Pittsford,
New York
|
+$4.52M |
| 3 |
Periscope Capital
Toronto,
Ontario, Canada
|
+$4.28M |
| 4 |
Weiss Asset Management
Boston,
Massachusetts
|
+$3.59M |
| 5 |
Mizuho Securities USA
New York
|
+$3.45M |
Top Sellers
CDIO Hedge Fund Activity: Q1 2022 in Review
30 of the 6,364 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q1 2022, worth a combined $52M.
Buyers outnumbered sellers: 30 funds opened new CDIO positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Saba Capital Management, opening a new position worth an estimated $4.64M.
- 30 institutional investors held Cardio Diagnostics (CDIO) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $52M of Cardio Diagnostics stock for Q1 2022.
- 30 funds opened new Cardio Diagnostics positions in Q1 2022 and 0 closed out, a net change of +30 holders.
- The largest Cardio Diagnostics buyer in Q1 2022 was Saba Capital Management, an estimated $4.64M added.
Based on aggregated 13F filings for Q1 2022.